10 / 10
I n t e r n a t i o n a l C o n f e r e n c e o n
Nuclear Medicine &
Radiation Therapy
Journal of Medical Physics and Applied Sciences
ISSN: 2574-285X
O c t o b e r 0 1 - 0 2 , 2 0 1 8
S t o c k h o l m , S w e d e n
Nuclear Medicine & Radiation Therapy 2018
Page 32
Biography
Derya ilem Ozdemir has completed her PhD from Ege Univer-
sity and postdoctoral studies from Stanford University School
of Medicine. She is working as an Associate Professor in Ege
University Faculty of Pharmacy. She has patent grants, more
than 25 papers in reputed journals and has been serving as an
Editorial Board Member of repute.
deryailem@gmail.comTargeting strategies of
radiopharmaceuticals by using drug
delivery systems for cancer imaging
Derya Ilem Ozdemir
Ege University, Turkey
Derya İlem Ozdemir, J. med phys & appl sci 2018, Volume: 3
DOI: 10.21767/2574-285X-C1-001
C
ancer isoneof the leadingcausesofmortalityworldwide. Usually, thediagnosis
of cancer at an early stage is important to facilitate proper treatment and
survival. Nuclear medicine has been successfully andwidely used in the diagnosis,
staging, therapy and monitoring of cancers by allowing scientists and physicians
to see what is happening in the body at a cellular level. Radiopharmaceuticals are
radioactive drugs which consist of a pharmaceutical compound and a radionuclide
part. After administration, the pharmaceutical compound moves to the target
tissue and the emitted radiation is detected by using gamma cameras. Since
high target/non-target uptake ratio is critical in nuclear imaging studies, likewise
conventional drugs radiopharmaceuticals are necessitating alternative and safer
treatment drug delivery strategies. Nanomedicine has developed to resolve issues
with poor drug solubility, nonspecific cytotoxicity, suboptimal pharmacokinetics
and pharmacodynamics, as well as poor bioavailability. In last decays, drug
delivery systems likewise include liposomes, polymeric nanoparticles, dendrimers,
micelles, mesoporous silica nanoparticles and gold nanoparticles, among
others are being evaluated as potential radionuclide carriers in radiopharmacy.
Scientists have designed radiopharmaceuticals to accumulate both active and
passive targeting. Passive targeting is a means by which drug can enter tumors
due to enhanced fenestrations in tumor vasculature and take advantage of the
enhanced permeability and retention (EPR) observed in solid tumor. The enhanced
permeability and retention (EPR) effect allows for some selective tumor uptake and
retention of nanoparticles due to the leaky tumor vasculature and poor lymphatic
drainage in tumors respectively. Also by surface modifications of nanoparticles
using polyethylene glycol (PEG), the circulation time of nanoparticles in the
blood can extend, while the mononuclear phagocytic system (MPS) recognition
and removal reducing. A multidisciplinary approach with collaborations between
theoretical and experimental scientists likewise radiopharmacist, pharmaceutical
technologist, medical doctors, chemist, biotechnologist etc., is therefore required
to improve new targeted radiopharmaceuticals in the clinic.